Money Too Tight To Mention At Motif After Iclaprim 'No' From FDA
Hit with a complete response letter from the US FDA for its antibiotic to treat ABSSSI, Motif needs to raise funds and fast to stay afloat and prepare a meeting package to discuss the next steps for iclaprim with the agency.
You may also be interested in...
The UK biotech is in dire need of further funding after US regulators requested an additional clinical trial for its much-delayed skin infection antibiotic.
The latest drug development news and highlights from our US FDA Performance Tracker.
Positive data from a second Phase III trial sets up Motif Bio for an NDA filing by the end of the year for novel antibiotic iclaprim – but success for the product has been a long time coming.